High-throughput screening for human galactokinase inhibitors

Klaas J. Wierenga, Kent Lai, Peter Buchwald, Manshu Tang

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Inherited deficiency of galactose-1-phosphate uridyltransferase (GALT) can result in a potentially lethal disorder called classic galactosemia. Although the neonatal lethality associated with this disease can be prevented through early diagnosis and a galactose-restricted diet, the lack of effective therapy continues to have consequences: developmental delay, neurological disorders, and premature ovarian failure are common sequelae in childhood and adulthood. Several lines of evidence indicate that an elevated level of galactose-1-phosphate (gal-1-p), the product of galactokinase (GALK), is a major, if not sole, pathogenic mechanism in patients with classic galactosemia. The authors hypothesize that elimination of gal-1-p production by inhibiting GALK will relieve GALT-deficient cells from galactose toxicity. To test this hypothesis, they obtained human GALK using a bacterial expression system. They developed a robust, miniaturized, high-throughput GALK assay (Z′ factor = 0.91) and used this assay to screen against libraries composed of 50,000 chemical compounds with diverse structural scaffolds. They selected 150 compounds that, at an average concentration of 33.3 μM, inhibited GALK activity in vitro more than 86.5% and with a reproducibility score of at least 0.7 for a confirmatory screen under identical experimental conditions. Of these 150 compounds, 34 were chosen for further characterization. Preliminary results indicated that these 34 compounds have potential to serve as leads to the development of more effective therapy of classic galactosemia.

Original languageEnglish
Pages (from-to)415-423
Number of pages9
JournalJournal of Biomolecular Screening
Volume13
Issue number5
DOIs
StatePublished - Aug 1 2008

Fingerprint

Galactokinase
Galactosemias
Screening
Throughput
Galactose
UTP-Hexose-1-Phosphate Uridylyltransferase
Assays
Primary Ovarian Insufficiency
Developmental Disabilities
Chemical compounds
Nutrition
Nervous System Diseases
Scaffolds
Libraries
Toxicity
Early Diagnosis
Diet
Therapeutics

Keywords

  • Classic galactosemia
  • Galactokinase (GALK)
  • Galactose-1-phosphate
  • Galactose-1-phosphate uridyltransferase (GALT)
  • GHMP small-molecule kinase
  • High-throughput screening
  • Small-molecule inhibitors

ASJC Scopus subject areas

  • Analytical Chemistry
  • Clinical Biochemistry
  • Biotechnology
  • Biochemistry
  • Molecular Biology

Cite this

High-throughput screening for human galactokinase inhibitors. / Wierenga, Klaas J.; Lai, Kent; Buchwald, Peter; Tang, Manshu.

In: Journal of Biomolecular Screening, Vol. 13, No. 5, 01.08.2008, p. 415-423.

Research output: Contribution to journalArticle

Wierenga, Klaas J. ; Lai, Kent ; Buchwald, Peter ; Tang, Manshu. / High-throughput screening for human galactokinase inhibitors. In: Journal of Biomolecular Screening. 2008 ; Vol. 13, No. 5. pp. 415-423.
@article{3a8510d335ad4ff384adc1090e92f3cb,
title = "High-throughput screening for human galactokinase inhibitors",
abstract = "Inherited deficiency of galactose-1-phosphate uridyltransferase (GALT) can result in a potentially lethal disorder called classic galactosemia. Although the neonatal lethality associated with this disease can be prevented through early diagnosis and a galactose-restricted diet, the lack of effective therapy continues to have consequences: developmental delay, neurological disorders, and premature ovarian failure are common sequelae in childhood and adulthood. Several lines of evidence indicate that an elevated level of galactose-1-phosphate (gal-1-p), the product of galactokinase (GALK), is a major, if not sole, pathogenic mechanism in patients with classic galactosemia. The authors hypothesize that elimination of gal-1-p production by inhibiting GALK will relieve GALT-deficient cells from galactose toxicity. To test this hypothesis, they obtained human GALK using a bacterial expression system. They developed a robust, miniaturized, high-throughput GALK assay (Z′ factor = 0.91) and used this assay to screen against libraries composed of 50,000 chemical compounds with diverse structural scaffolds. They selected 150 compounds that, at an average concentration of 33.3 μM, inhibited GALK activity in vitro more than 86.5{\%} and with a reproducibility score of at least 0.7 for a confirmatory screen under identical experimental conditions. Of these 150 compounds, 34 were chosen for further characterization. Preliminary results indicated that these 34 compounds have potential to serve as leads to the development of more effective therapy of classic galactosemia.",
keywords = "Classic galactosemia, Galactokinase (GALK), Galactose-1-phosphate, Galactose-1-phosphate uridyltransferase (GALT), GHMP small-molecule kinase, High-throughput screening, Small-molecule inhibitors",
author = "Wierenga, {Klaas J.} and Kent Lai and Peter Buchwald and Manshu Tang",
year = "2008",
month = "8",
day = "1",
doi = "10.1177/1087057108318331",
language = "English",
volume = "13",
pages = "415--423",
journal = "Journal of Biomolecular Screening",
issn = "1087-0571",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - High-throughput screening for human galactokinase inhibitors

AU - Wierenga, Klaas J.

AU - Lai, Kent

AU - Buchwald, Peter

AU - Tang, Manshu

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Inherited deficiency of galactose-1-phosphate uridyltransferase (GALT) can result in a potentially lethal disorder called classic galactosemia. Although the neonatal lethality associated with this disease can be prevented through early diagnosis and a galactose-restricted diet, the lack of effective therapy continues to have consequences: developmental delay, neurological disorders, and premature ovarian failure are common sequelae in childhood and adulthood. Several lines of evidence indicate that an elevated level of galactose-1-phosphate (gal-1-p), the product of galactokinase (GALK), is a major, if not sole, pathogenic mechanism in patients with classic galactosemia. The authors hypothesize that elimination of gal-1-p production by inhibiting GALK will relieve GALT-deficient cells from galactose toxicity. To test this hypothesis, they obtained human GALK using a bacterial expression system. They developed a robust, miniaturized, high-throughput GALK assay (Z′ factor = 0.91) and used this assay to screen against libraries composed of 50,000 chemical compounds with diverse structural scaffolds. They selected 150 compounds that, at an average concentration of 33.3 μM, inhibited GALK activity in vitro more than 86.5% and with a reproducibility score of at least 0.7 for a confirmatory screen under identical experimental conditions. Of these 150 compounds, 34 were chosen for further characterization. Preliminary results indicated that these 34 compounds have potential to serve as leads to the development of more effective therapy of classic galactosemia.

AB - Inherited deficiency of galactose-1-phosphate uridyltransferase (GALT) can result in a potentially lethal disorder called classic galactosemia. Although the neonatal lethality associated with this disease can be prevented through early diagnosis and a galactose-restricted diet, the lack of effective therapy continues to have consequences: developmental delay, neurological disorders, and premature ovarian failure are common sequelae in childhood and adulthood. Several lines of evidence indicate that an elevated level of galactose-1-phosphate (gal-1-p), the product of galactokinase (GALK), is a major, if not sole, pathogenic mechanism in patients with classic galactosemia. The authors hypothesize that elimination of gal-1-p production by inhibiting GALK will relieve GALT-deficient cells from galactose toxicity. To test this hypothesis, they obtained human GALK using a bacterial expression system. They developed a robust, miniaturized, high-throughput GALK assay (Z′ factor = 0.91) and used this assay to screen against libraries composed of 50,000 chemical compounds with diverse structural scaffolds. They selected 150 compounds that, at an average concentration of 33.3 μM, inhibited GALK activity in vitro more than 86.5% and with a reproducibility score of at least 0.7 for a confirmatory screen under identical experimental conditions. Of these 150 compounds, 34 were chosen for further characterization. Preliminary results indicated that these 34 compounds have potential to serve as leads to the development of more effective therapy of classic galactosemia.

KW - Classic galactosemia

KW - Galactokinase (GALK)

KW - Galactose-1-phosphate

KW - Galactose-1-phosphate uridyltransferase (GALT)

KW - GHMP small-molecule kinase

KW - High-throughput screening

KW - Small-molecule inhibitors

UR - http://www.scopus.com/inward/record.url?scp=44849109699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44849109699&partnerID=8YFLogxK

U2 - 10.1177/1087057108318331

DO - 10.1177/1087057108318331

M3 - Article

C2 - 18490662

AN - SCOPUS:44849109699

VL - 13

SP - 415

EP - 423

JO - Journal of Biomolecular Screening

JF - Journal of Biomolecular Screening

SN - 1087-0571

IS - 5

ER -